The ADHD drug, both the extended release and immediate release version, is on back-order with Sandoz Inc., a division of Novartis AG, because of increased demand. Teva expects a full recovery for all inventory and orders in the coming weeks, which should resolve the disruption at the pharmacy level, a spokeswoman for the company said. The FDA is monitoring the supply of ADHD medications, but hasn’t reported a shortage of Adderall or the generic version, but did from September 2019 through May 2022.Read Long Article
